Promising results for once-monthly HIV treatment
A once-a-month injection could replace daily triple therapy in HIV management according to a report in PharmaTimes.
The Phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression) study was designed to determine whether HIV-1-infected adults who had maintained viral suppression for at least six months, on a daily oral regimen comprised of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, maintained similar rates of viral suppression when switched to a long-acting, injectable regimen of ViiV’s cabotegravir and Janssen’s rilpivirine.
Initial results show that the two-drug regimen, injected once a month, had similar efficacy to a standard of care, daily, oral three-drug regimen at week 48, meeting the primary endpoint for non-inferiority.
John Pottage, chief scientific and medical officer of ViiV Healthcare, which is majority owned by GSK, says: ‘This novel approach is another step towards potentially reducing the treatment burden for people living with HIV. If approved, this regimen would give people living with HIV one month between each dose of antiretroviral therapy, changing HIV treatment from 365 dosing days per year, to just 12.’